Perspective Therapeutics, Inc. Logo

Perspective Therapeutics, Inc.

Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.

CATX | US

Overview

Corporate Details

ISIN(s):
US46489V1044 (+1 more)
LEI:
Country:
United States of America
Address:
2401 ELLIOTT AVENUE, 98121 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company pioneering advanced treatments for cancer. The company specializes in developing image-guided, targeted alpha-particle therapies (TATs). Its proprietary technology platform uses a revolutionary lead-212 (Pb-212) based approach, conjugating radioisotopes to high-affinity targeting peptides. This theranostic method allows physicians to first image tumors to confirm targets and then deliver potent, short-range alpha radiation directly to cancer cells, aiming to maximize efficacy while minimizing damage to surrounding healthy tissue. The company's clinical pipeline is focused on oncology, with programs targeting melanoma, neuroendocrine tumors, and other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Perspective Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perspective Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perspective Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO
Zentalis Pharmaceuticals, Inc. Logo
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
United States of America
ZNTL

Talk to a Data Expert

Have a question? We'll get back to you promptly.